Rodeo Therapeutics Corp.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Rodeo Therapeutics Corp.
Amgen CEO Bradway On Deals: Good (Smaller) Opportunities Are Vast
Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between.
Amgen Builds Out Antibody Interests With $2.5bn Teneobio Buy
Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.
Amgen Ropes Second M&A Deal Of 2021 In Rodeo Buyout
Deal snapshot: Rodeo’s preclinical work in modulating the 15-PDGH enzyme may yield novel regenerative therapies for inflammation, Amgen says, including GI and post-bone marrow transplant indications.
Generics Firms Can't Halt Maryland's 'Price Gouging' Law
Judge rejects Association for Accessible Medicines' bid for preliminary injunction, but industry can still pursue claims the statute's language is unconstitutionally vague; law goes into effect Oct. 1.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Amgen, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.